Table 3 Relative risk estimates for REN and AGT interactions:
A: Relative risk estimates (95% CI; p-value) for fetal RENhaplotypes when mothers carry the protective AGThaplotype C-T-A (n = 57 family-triads) | |||
|---|---|---|---|
RENhaplotype | Frequency (%) | Single dose | Double dose |
A-G-C | 61.3 | 0.62 (0.22-1.71); 0.36 | 0.33 (0.09-1.19); 0.09 |
A-t-C | 29.4 | 1.03 (0.38-2.82); 0.96 | 0.62 (0.14-2.79); 0.54 |
c-G-t | 8.9 | 1.29 (0.50-3.25); 0.59 | Not estimable |
B: Relative risk estimates (95% CI; p-value) for fetal REN haplotypes when mothers do not carry the protective AGT haplotype C-T-A (n = 27 family-triads) | |||
REN haplotype | Frequency (%) | Single dose | Double dose |
A-G-C | 55.2 | 1.53 (0.16-14.90); 0.71 | 1.0 (0.08-12.4); 0.99 |
A-t-C | 38.0 | 2.40 (0.24-24.10); 0.46 | 0.89 (0.06-15.20); 0.93 |
c-G-t | 5.8 | 0.60 (0.09-4.14); 0.60 | Not estimable |